Solid Biosciences Inc (NASDAQ: SLDB) is a clinical-stage biotherapeutics company focused on developing gene therapy treatments for rare diseases. The company generates no product revenue and funds operations through equity issuances, including private placements and at-the-market offerings. As of the 10-K filed March 19, 2026, Solid Biosciences had four active development programs: SGT-003, SGT-501, SGT-212, and SGT-601. Total research and development expenses were $140.3 million for the year ended December 31, 2025, up 45.5% from $96.4 million in FY2024, driven primarily by SGT-003, which consumed $59.0 million in allocated R&D spend in FY2025 versus $15.2 million in FY2024. General and administrative expenses were $38.9 million in FY2025. The company reported a loss from operations of $179.2 million in FY2025. Financing activities provided $194.4 million in FY2025, almost entirely from equity issuances. CEO is Alexander Cumbo and CFO is Kevin Tan, with Ian F. Smith serving as Executive Chairman.

Revenue model

No product revenue. Operations are funded entirely through equity capital raises, including private placements and at-the-market common stock offerings. Interest income on available-for-sale securities ($9.9 million in FY2025) partially offsets operating losses.

Products and services

Four pipeline programs as of the 10-K filed March 19, 2026: SGT-003 (largest R&D spend at $59.0 million in FY2025), SGT-501 ($9.6 million in FY2025), SGT-212 ($5.5 million in FY2025), and SGT-601 ($7.8 million in FY2025). All are pre-commercial gene therapy candidates.

Customers and end markets

No commercial customers as of the filing date. End market is patients with rare diseases targeted by gene therapy. No customer concentration data applicable.

Value-chain role

Early-stage drug developer. The company files patent applications on its candidates and relies on intellectual property protection for future commercial potential. No manufacturing, distribution, or commercial sales operations are disclosed in the excerpts.

Geographic exposure

Primary operations in the United States. Regulatory references include FDA approval pathways and European GDPR compliance obligations, suggesting some international research or data-processing activity, but no geographic revenue breakdown is applicable given no product revenue.

Source: SEC 10-K, filed 2026-03-19

Industry: Biological Products, (No Diagnostic Substances) Peers: Akebia Therapeutics Inc Atreca, Inc. BioVie Inc Disc Medicine Inc GT Biopharma Inc ImmuCell Corp EOM Pharmaceutical Holdings, Inc. Palatin Technologies Inc Surface Oncology, Inc.